Literature DB >> 21817117

Bronchogenic squamous cell carcinoma mass with central photopenia on FDG-PET scan.

Vikram Sahni1, Sebnem Guvenc-Tuncturk, Harman S Paintal, Ware G Kuschner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21817117      PMCID： PMC3280459          DOI： 10.3121/cmr.2011.1013

Source DB:  PubMed          Journal:  Clin Med Res        ISSN： 1539-4182


× No keyword cloud information.
  6 in total

1.  Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome.

Authors:  Amir Onn; Du Hwan Choe; Roy S Herbst; Arlene M Correa; Reginald F Munden; Mylene T Truong; Ara A Vaporciyan; Takeshi Isobe; Michael Z Gilcrease; Edith M Marom
Journal:  Radiology       Date:  2005-10       Impact factor: 11.105

2.  Patterns of abnormal FDG uptake by various histological types of non-small cell lung cancer at initial staging by PET.

Authors:  C Y Wong; R Nuñez; P Bohdiewicz; R J Welsh; G W Chmielewski; K P Ravikrishnan; J C Hill; S E Pursel; D Fink-Bennett; H Balon; C Dickinson; H J Dworkin
Journal:  Eur J Nucl Med       Date:  2001-11

3.  Should cavitated bronchopulmonary cancers be considered a separate entity?

Authors:  J Mouroux; B Padovani; D Elkaïm; H Richelme
Journal:  Ann Thorac Surg       Date:  1996-02       Impact factor: 4.330

4.  Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.

Authors:  Edith M Marom; Carlos H Martinez; Mylene T Truong; Xiudong Lei; Bradley S Sabloff; Reginald F Munden; Gregory W Gladish; Roy S Herbst; Rodolfo C Morice; David J Stewart; Carlos A Jimenez; George R Blumenschein; Amir Onn
Journal:  J Thorac Oncol       Date:  2008-04       Impact factor: 15.609

5.  Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features.

Authors:  G Pentheroudakis; L Kostadima; G Fountzilas; A Kalogera-Fountzila; G Klouvas; C Kalofonos; N Pavlidis
Journal:  Lung Cancer       Date:  2004-09       Impact factor: 5.705

6.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Authors:  David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.